tbuckley/cabot-search huggingface dataset:
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
Authors: Z. Piotrowska, D.B. Costa, G.R. Oxnard, M. Huberman, J.F. Gainor, I.T. Lennes, A. Muzikansky, A.T. Shaw, C.G. Azzoli, R.S. Heist, L.V. Sequist
Journal: Annals of Oncology (2018)

BackgroundThere are currently no approved targeted therapies for non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (ins20), a subgroup of EGFR mutations that are generally refractory to first/second generation EGFR inhibitors. We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20.Patients and methodsTwenty-nine patients with stage IV NSCLC with EGFR ins20 identified on local testing and at least one prior therapy were enrolled on the trial between August 2013 and October 2016. The primary end point was objective response rate (ORR), with a pre-determined target rate of effectiveness [defined as the rate of partial response (PR) plus stable disease (SD) lasting ≥3 months] of 20%. Secondary end points were PFS, overall survival (OS), safety and response by EGFR ins20 subtype.ResultsAmong the 29 patients (18 females, median age 60 years) the ORR was 17%, median progression-free survival was 2.9 months (95% CI 1.4–5.6) and median OS (mOS) was 13 months (95% CI 4.9–19.5). The results exceeded the pre-determined target rate of effectiveness with 11/29 (38%) patients having a PR or an SD ≥3 months. The most common luminespib-related toxicities were diarrhea (83%), visual changes (76%) and fatigue (45%). All study treatment was stopped on 28 February 2017 due to dissolution of study drug availability; 3 patients were on treatment at study termination.ConclusionThe study met its primary end point, suggesting that luminespib may be an active therapy for advanced NSCLC patients with EGFR ins20. Luminespib is generally well-tolerated, though reversible low-grade ocular toxicity is common. Further study of luminespib and other hsp90 inhibitors in this population is warranted.Study registration (ClinicalTrials.gov)NCT01854034.
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
Authors: P.F. Conte, V. Guarneri, G. Bisagni, F. Piacentini, A.A. Brandes, L. Cavanna, F. Giotta, M. Aieta, V. Gebbia, A. Frassoldati, A. Musolino, O. Garrone, C. Taverniti, A. Rimanti, S. Sarti, D. Rubino, A. Bologna, R. Vicini, S. Balduzzi, R. D'Amico
Journal: Annals of Oncology (2018)
P2.01-74 Docetaxel-Related Febrile Neutropenia (FN) And Patient Reported Symptoms/ QOL (PROs) in East Asian (EA) and Non-EA Patients
Authors: Y. Omori, A. Brnabic, N. Rajan, S. Enatsu, J. Shih, J. Kim, K. Park
Journal: Journal of Thoracic Oncology (2018)
P3.04-12 Prognostic and Predictive Role of Peripheral Blood Biomarkers in NSCLC Patients Treated with Checkpoint, a Single-Center Experience.
Authors: A. Prelaj, P. Pizzutilo, M. Montrone, F. Cassano, F. Pesola, V. Lapadula, P. Petrillo, N. Varesano, V. Lamorgese, A. Mastrandrea, D. Ricci, A. Catino, D. Galetta
Journal: Journal of Thoracic Oncology (2018)
P1.09-22 Detection of ALK Gene Rearrangement in FFPE Tissues of Non-Small Cell Lung Cancer Using in Situ RNA Hybridization
Authors: S. Wu, N. Li, X. Shi, M. Wang, H. Sun, X. Ma, Z. Liang, E. Park, R. Momroe, X. Zeng
Journal: Journal of Thoracic Oncology (2018)
OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
Authors: T. Nakano, M. Okada, T. Kijima, K. Aoe, T. Kato, N. Fujimoto, K. Nakagawa, Y. Takeda, T. Hida, K. Kanai, F. Imamura, S. Oizumi, T. Takahashi, M. Takenoyama, H. Tanaka, Y. Ohe
Journal: Journal of Thoracic Oncology (2018)
ES03.05 Role of Surgery in T0 Mesothelioma
Authors: S. Hasegawa, H. Kodama, M. Hashimoto, A. Fukuda, T. Nakamichi, A. Nakamura, A. Kuroda, T. Takuwa, S. Matsumoto, Y. Okumura, K. Yamakado, T. Kijima, N. Kondo
Journal: Journal of Thoracic Oncology (2018)
Aflibercept in combination with irinotecan, fluorouracil and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal cancer (mCRC) patients: A phase II multicentric study
Authors: A. Lapeyre-Prost, S. Pernot, J. Sigrand, F. Mary, K. Le Malicot, T. Aparicio, L. Dahan, F.-X. Caroli-Bosc, T. Lecomte, S. Racine Doat, L. Marthey, J. Desrame, C. Lepage, J. Taieb
Journal: Annals of Oncology (2018)
P1.12-21 Developing a Real-World 3L Comparator to CheckMate 032: Overall Survival (OS) in Patients with Small Cell Lung Cancer (SCLC)
Authors: L. Schwartzberg, B. Korytowsky, J. Penrod, Y. Yuan, T. Gu, T. Le, P. Abraham, G. Selvaggi
Journal: Journal of Thoracic Oncology (2018)
Serum biomarkers during the first cycle of anti-PD-1 antibody therapies in non-small cell lung cancer
Authors: T. Ota, T. Takeda, T. Fukui, Y. Nakahara, K. Kudo, T. Okabe, H. Hayashi, S. Otani, Y. Hiyoshi, K. Yonesaka, T. Sugiura, T. Suzumura, M. Terashima, Y. Nakano, Y. Hasegawa, H. Tsukuda, K. Matsui, N. Masuda, M. Fukuoka
Journal: Annals of Oncology (2018)
OA12.06 Mutational Landscape of BRAF V600E Positive Lung Cancer Patients Following BRAF Directed Therapy Failure
Authors: A. Dimou, T. Ng, A. Chalmers, M. Devitt, A. Le, V. Malhotra, V. Malhotra, R. Hall, T. Rich, W. Akerley, J. Zhang, D. Aisner, R. Camidge, R. Doebele
Journal: Journal of Thoracic Oncology (2018)
Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): The CIROCO study
Authors: J. Desrame, J. Loup Mouysset, T. Altwegg, L. Zelek, N. Baize
Journal: Annals of Oncology (2018)
MA02.02 Multistate Healthcare Network Underutilizes Valuable End-of-Life Resources in Stage IV Non-Small Cell Lung Cancer
Authors: J. Rayburn, C. Wilshire, C. Gilbert, R. Weerasinghe, B. Louie, R. Aye, A. Farivar, E. Vallieres, J. Gorden
Journal: Journal of Thoracic Oncology (2018)
Proton-Pump Inhibitor Prophylaxis in the ICU — Benefits Worth the Risks?
Authors: Alan Barkun, Marc Bardou
Journal: New England Journal of Medicine (2018)

Critical illness can disrupt local and systemic mechanisms that protect against upper gastrointestinal bleeding, a condition that may be associated with increased mortality,1 particularly among patients receiving extracorporeal life support.2 On the basis of randomized trials performed over a period of 40 years,3 most guidelines recommend preventive therapy with either histamine H2–receptor antagonists or proton-pump inhibitors (PPIs) for patients in the intensive care unit (ICU) who are at risk for the development of stress ulceration and bleeding. A review of this approach is timely, owing to a number of considerations. First, contemporary observations suggest that stress-ulcer bleeding may be less . . .
Liquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study
Authors: L. Bonanno, E. Zulato, I. Attili, A. Pavan, P. Del Bianco, G. Nardo, M. Verza, L. Pasqualini, G. Pasello, G. Zago, S. Frega, M. Fassan, F. Calabrese, A. Amadori, V. Guarneri, P.F. Conte, S. Indraccolo
Journal: Annals of Oncology (2018)
ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma
Authors: S. Chowdhury, S. Feyerabend, Y. Loriot, A. Necchi, S. Gupta, D.H. Josephs, A. Rodríguez-Vida, S. Srinivas, Y. Zakharia, D. Nepert, K. Wride, D. Thomas, A. Loehr, A.D. Simmons, P. Grivas
Journal: Annals of Oncology (2018)
Lack of efficiency of precision oncology with target-based investigational treatments for patients in early phase clinical trials based on pre-screened molecular alterations
Authors: B. Doger de Spéville, V. Moreno, T. Hernandez, V. Boni, M.J. de Miguel, F. Rojo, F. Lopez-Rios, E. Calvo
Journal: Annals of Oncology (2018)
Cancer situation in Sub-Saharan countries: Development of educational, diagnosis and treatment plans
Authors: J.C. de la Torre-Montero, N. Gil-Gómez, J.L. Ribes bernal, N. Domenech Climent, A. Ojer Perea, P. Beorlegui Murillo, J.M. Gavala Arjona, R. Cumplido Corbacho, I. Magallon Pedrera, M.A. Peñuelas Saiz
Journal: Annals of Oncology (2018)
Abstract 295: Aortic Valve Calcium Scores Are Strong Predictors of Aortic Stenosis in a Population-Based Setting: The AGES-Reykjavik Study
Authors: David S Owens, Jonathan F Plehn, Sigurdur Sigurdsson, Jeffrey L Probstfield, Lenore J Launer, Gudny Eiriksdottir, Vilmundur Gudnason, Tamara B Harris, Kevin D O'Brien
Journal: Circulation (2009)
The influence of the surgical approach in women diagnosed with breast neoplasia
Authors: R.A. de Araujo, C.P. Nascimento, C.L.P. Da Cunha, E.D.C. Marinho, E.R.T. Mosca, F.A.C. Da Luz, P.F.R. Delfino, R.M. Antonioli, T.R. Mendes, M.J.B. Silva
Journal: Annals of Oncology (2018)
MA06.03 PD-1 and Id-1 Combined Blockade Impacts Tumor Growth and Survival Through PD-L1 Expression and Tumor Infiltration by Immune-Related Cells
Authors: I. Gil-Bazo, I. Baraibar, M. Roman Moreno, I. Lopez, J. Corral, J. Lasarte, A. Calvo, S. Vicent, D. Ajona
Journal: Journal of Thoracic Oncology (2018)
Patterns of germline and somatic mutations in 16 mismatch repair associated genes analyzed with next generation sequencing (NGS) in colorectal cancer with EMAST (+) and/or MSI-high
Authors: S.-C. Chang, P.-C. Lin, C.-C. Lin, J.-K. Lin, Y.-T. Lan, J.-K. Jiang, S.-H. Yang, C.-H. Lin, W.-S. Chen
Journal: Annals of Oncology (2018)
Analysis of functional androgen receptor-pathway activity to predict response to androgen deprivation therapy in salivary duct carcinoma
Authors: W. van Boxtel, I. van Engen-van Grunsven, D. van Strijp, J.B.A. van Zon, M.J.L. Ligtenberg, G. Verhaegh, J. Schalken, S. Neerken, A. van de Stolpe, C.M.L. van Herpen
Journal: Annals of Oncology (2018)
P3.07-04 Massage Chair Encounters Favorably Impact Outpatient Oncology RN’s Perceived Level of Stress, BP, HR
Authors: M.E. Hand, S. Duveneck, J. Margolis, M. Zindrick, J. Baptista, K. Ruestow, B. Staffileno, S. Potoczny
Journal: Journal of Thoracic Oncology (2018)
Clinical outcomes according to age and comorbidities in the OSCAR UK observational study of front-line bevacizumab (BEV)-containing therapy for advanced ovarian cancer (aOC)
Authors: M. Hall, G. Bertelli, L. Li, C. Green, S. Chan, C.C. Yeoh, J. Hasan, A. Ograbek, T.J. Perren
Journal: Annals of Oncology (2018)
Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
Authors: Zhi Huang, Wei Zhou, Yongtao Li, Mei Cao, Tianqi Wang, Yakun Ma, Qingxiang Guo, Xin Wang, Chao Zhang, Chenglan Zhang, Wenzhi Shen, Yanhua Liu, Yanan Chen, Jianyu Zheng, Shengyong Yang, Yan Fan, Rong Xiang
Journal: Theranostics (2018)

Despite initial progress in preclinical models, most known histone deacetylase inhibitors (HDACis) used as a single agent have failed to show clinical benefits in nearly all types of solid tumours. Hence, the efficacy of HDACis in solid tumours remains uncertain. Herein, we developed a hybrid HDAC inhibitor that sensitized solid tumours to HDAC-targeted treatment. Methods: A hybrid molecule, Roxyl-zhc-84 was designed and synthesized with novel architecture. The pharmacokinetics and toxicity of Roxyl-zhc-84 were analysed. The antitumour effects of Roxyl-zhc-84 on solid tumours were investigated by assessing cell growth, apoptosis and cell cycle in vitro and in three in vivo mouse models and compared to those of corresponding control inhibitors alone or in combination. Gene set enrichment analysis was performed, and relevant JAK1-STAT3-BCL2 signalling was identified in vitro and in vivo in mechanistic studies. Results: Roxyl-zhc-84 showed excellent pharmacokinetics and low toxicity. The novel hybrid inhibitor Roxyl-zhc-84 induced cell apoptosis and G1-phase arrest in breast cancer and ovarian cancer cell lines. In three mouse models, oral administration of Roxyl-zhc-84 led to significant tumour regression without obvious toxicity. Moreover, Roxyl-zhc-84 dramatically improved the limited response of traditional HDAC inhibitors in solid tumours via overcoming JAK1-STAT3-BCL2-mediated drug resistance. Roxyl-zhc-84 treatment exhibited vastly superior efficacy than the combination of HDAC and JAK1 inhibitors both in vitro and in vivo. Conclusion: Concurrent inhibition of HDAC and CDK using Roxyl-zhc-84 with additional JAK1 targeting resolved the limited response of traditional HDAC inhibitors in solid tumours via overcoming JAK1-STAT3-BCL2-mediated drug resistance, providing a rational multi-target treatment to sensitize solid tumours to HDACi therapy.
P2.01-117 Concurrent Gene Alterations in Treatment-Naïve EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Authors: J. Zhao, M. Zhang, J. Zhang, L. Chen, R. Guo, G. Lin, T. Yin, H. Shi, W. Wang, C. Xu, R. Chen, X. Xia
Journal: Journal of Thoracic Oncology (2018)
Diagnostic yield of magnetically assisted capsule endoscopy versus gastroscopy in recurrent and refractory iron deficiency anemia
Authors: Hey-Long Ching, Melissa F. Hale, Matthew Kurien, Jennifer A. Campbell, Stefania Chetcuti Zammit, Ailish Healy, Victoria Thurston, John M. Hebden, Reena Sidhu, Mark E. McAlindon
Journal: Endoscopy (2018)

Small-bowel capsule endoscopy is advocated and repeat upper gastrointestinal (GI) endoscopy should be considered for evaluation of recurrent or refractory iron deficiency anemia (IDA). A new device that allows magnetic steering of the capsule around the stomach (magnetically assisted capsule endoscopy [MACE]), followed by passive small-bowel examination might satisfy both requirements in a single procedure.In this prospective cohort study, MACE and esophagogastroduodenoscopy (EGD) were performed in patients with recurrent or refractory IDA. Comparisons of total (upper GI and small bowel) and upper GI diagnostic yields, gastric mucosal visibility, and patient comfort scores were the primary end points.49 patients were recruited (median age 64 years; 39 % male). Combined upper and small-bowel examination using the new capsule yielded more pathology than EGD alone (113 vs. 52; P < 0.001). In upper GI examination (proximal to the second part of the duodenum, D2), MACE identified more total lesions than EGD (88 vs. 52; P < 0.001). There was also a difference if only IDA-associated lesions (esophagitis, altered/fresh blood, angioectasia, ulcers, and villous atrophy) were included (20 vs. 10; P = 0.04). Pathology distal to D2 was identified in 17 patients (34.7 %). Median scores (0 - 10 for none - extreme) for pain (0 vs. 2), discomfort (0 vs. 3), and distress (0 vs. 4) were lower for MACE than for EGD (P < 0.001).Combined examination of the upper GI tract and small bowel using the MACE capsule detected more pathology than EGD alone in patients with recurrent or refractory IDA. MACE also had a higher diagnostic yield than EGD in the upper GI tract and was better tolerated by patients.
Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)
Authors: V. Moreno, M. Gil-Martin, M. Johnson, R. Aljumaily, P. Lopez Criado, D.W. Northfelt, M. Crittenden, S. Jabbour, L. Rosen, P. Garrido Lopez, A. Hervás Morón, P. Rietschel, K.K. Mohan, J. Li, E. Stankevich, T. Rowlands, M. Feng, I. Lowy, M.G. Fury
Journal: Annals of Oncology (2018)
FAT1 on YAP1-TEAD1 interaction augments oncogenic potential of GBM cells
Authors: Y. Gupta, S.S. Shivajirao, K. Irshad, B. Dikshit, T. Srivastava, P.P. Chattopadhyay, S. Sinha, K. Chosdol
Journal: Annals of Oncology (2018)
Optimisation of chemotherapy in the era of immunotherapy
Authors: René Boosman, Jacobus (Sjaak) Adrianus Burgers
Journal: European Respiratory Journal (2018)

<b>Even in the era of immuno- and personalised therapy, optimal use of old-fashioned chemotherapy is of utmost importance, also for patients with renal insufficiency or declining renal function</b>http://ow.ly/rdlH30m4V1N
Can measuring quality lead to improvement? Evidence from international participants of ASCO’s quality oncology practice initiative (QOPI®) during 2015-2017
Authors: M. Jahanzeb, T. Gilmore, A. Roach, S.S. Grubbs, D. Blayney, J. Hamm, A. Kamal, R.J. Kelly, E. Martin, J.A. Sanchez, R. Siegel, S.T.S. Crist, J. Rosenthal, C. Hendricks
Journal: Annals of Oncology (2018)
Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma
Authors: K.L. Moek, W.M. Fiedler, J.C. von Einem, H.M. Verheul, T. Seufferlein, D.J. de Groot, V. Heinemann, M. Kebenko, C.W. Menke-van der Houven van Oordt, T.J. Ettrich, E. Rasmussen, P. Bogner, B. Sable, S. Stienen, E.G.E. de Vries
Journal: Annals of Oncology (2018)
P1.04-35 Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
Authors: A. Vergnenegre, M. Geier, F. Guisier, R. Lamy, B. Comet, G. Le Garff, P. Do, H. Janicot, H. Morel, C. Decroisette, M. Andre, L. Falchero, N. Paleiron, I. Monnet
Journal: Journal of Thoracic Oncology (2018)
Abstract 18041: The Novel Mineralocorticoid Receptor Antagonist Finerenone Attenuates Neointima Formation After Vascular Injury
Authors: Daniel Sedding, Robert Musmann, Jochen Dutzmann, Peter Kolkhof, Johann Bauersachs
Journal: Circulation (2016)

Introduction: Ischemic cardiomyopathy as a result of coronary artery disease is the leading cause for heart failure. Finerenone, a novel nonsteroidal mineralocorticoid receptor (MR) antagonist, hol...
Analysis of BRCAness with MLPA in pancreatic ductal adenocarcinoma patients using FFPE sample obtained via EUS-FNAB
Authors: K. Okuwaki, H. Imaizumi, H. Masutani, T. Yoshida, M. Kida, T. Iwai, H. Yamauchi, T. Kaneko, R. Hasegawa, E. Miyata, K. Adachi, M. Tadehara, W. Koizumi
Journal: Annals of Oncology (2018)
Direct conversion of mouse astrocytes into neural progenitor cells and specific lineages of neurons
Authors: Kangmu Ma, Xiaobei Deng, Xiaohuan Xia, Zhaohuan Fan, Xinrui Qi, Yongxiang Wang, Yuju Li, Yizhao Ma, Qiang Chen, Hui Peng, Jianqing Ding, Chunhong Li, Yunlong Huang, Changhai Tian, Jialin C. Zheng
Journal: Translational Neurodegeneration (2018)

Cell replacement therapy has been envisioned as a promising treatment for neurodegenerative diseases. Due to the ethical concerns of ESCs-derived neural progenitor cells (NPCs) and tumorigenic potential of iPSCs, reprogramming of somatic cells directly into multipotent NPCs has emerged as a preferred approach for cell transplantation.Mouse astrocytes were reprogrammed into NPCs by the overexpression of transcription factors (TFs) Foxg1, Sox2, and Brn2. The generation of subtypes of neurons was directed by the force expression of cell-type specific TFs Lhx8 or Foxa2/Lmx1a.Astrocyte-derived induced NPCs (AiNPCs) share high similarities, including the expression of NPC-specific genes, DNA methylation patterns, the ability to proliferate and differentiate, with the wild type NPCs. The AiNPCs are committed to the forebrain identity and predominantly differentiated into glutamatergic and GABAergic neuronal subtypes. Interestingly, additional overexpression of TFs Lhx8 and Foxa2/Lmx1a in AiNPCs promoted cholinergic and dopaminergic neuronal differentiation, respectively.Our studies suggest that astrocytes can be converted into AiNPCs and lineage-committed AiNPCs can acquire differentiation potential of other lineages through forced expression of specific TFs. Understanding the impact of the TF sets on the reprogramming and differentiation into specific lineages of neurons will provide valuable strategies for astrocyte-based cell therapy in neurodegenerative diseases.
P3.01-11 Depression and Inflammation in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Authors: A. Cardona, O. Arrieta, L. Rojas, Z. Zatarain-Barrón, L. Ricaurte, A. Ruiz-Patiño, C. Martin, H. Carranza, C. Vargas, J. Otero, L. Corrales
Journal: Journal of Thoracic Oncology (2018)
P1.13-18 Exploring the Resistance Mechanism of Osimertinib and Monitoring the Treatment Response Using Plasma ctDNA in Chinese NSCLC Patients
Authors: Y. Shi, P. Xing, X. Han, S. Wang, Y. Liu, P. Liu, J. Li, L. Chang, Y. Guan, Z. Zhang, D. Wu, J. Yao, Y. Xin
Journal: Journal of Thoracic Oncology (2018)
Expression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical response to CDK4/6 inhibitors in breast cancer
Authors: S. Crucitta, M. Del Re, A. Fontana, I. Bertolini, E. Rofi, C. De Angelis, L. Diodati, D. Cavallero, B. Salvadori, A. Falcone, R. Morganti, R. Danesi
Journal: Annals of Oncology (2018)
P2.04-06 Increased Plasma Cell % and Decreased B-Cells in Tumor Immune Infiltrates Are Associated with Worse Prognosis in Lung Adenocarcinomas
Authors: H.E. Lee, L. Luo, T. Kroneman, M. Passow, K. Del Rosario, M. Christensen, M. Francis, J. O’Shaughnessy, A. Blahnik, P. Yang, E. Yi
Journal: Journal of Thoracic Oncology (2018)
A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC)
Authors: R.E. O’Cearbhaill, A. Wolfer, P. Disilvestro, D.M. O’Malley, P. Sabbatini, L. Shohara, P.O. Schwarzenberger, T. Ricciardi, M. Macri, A. Ryan, R.R. Venhaus, J.K. Bryan, P. Wong, K. Homicsko, L. Kandalaft, S. Rusakiewicz, A. Harari, B.J. Monk, G. Coukos
Journal: Annals of Oncology (2018)
Correlation beetween the expression of androgens receptor (RA) and histopathological characteristics and survival parameters of breast cancer
Authors: I.D. Sillero, A. López González, L.F. Sanchez Cousido, M. López-Flores, E. Honrado Franco, L. Lopez Gonzalez, O. Sanz, C. Castañón López, A. García Palomo
Journal: Annals of Oncology (2018)
Involving clinicians in sports medicine and physiotherapy research: ‘design thinking’ to help bridge gaps between practice and evidence
Authors: Jean-Francois Esculier, Christian Barton, Rod Whiteley, Christopher Napier
Journal: British Journal of Sports Medicine (2018)

Bridging the gap between current practice and evidence is not easy in sports medicine. Research findings must be relevant to real-world clinical practice and effectively reach practitioners, who then must understand, interpret and apply them to their patients. Any change in practice requires clinically meaningful research to spark interest among clinicians. The ‘Ikea effect’—where novice builders value their own creations as highly as the work of experts1—provides some insight into a strategy which will help drive clinical research uptake. Specifically, engaging clinicians in the scientific process is key to ensuring effective translation of research to patient care.

Sports medicine research needs a ‘design thinking’ approach that prioritises the needs of the end user.2 Design thinking would have clinicians guiding researchers in designing research questions based on experience and interaction with patients to solve practice-generated problems.3 As an example, patients are unlikely to engage in a treatment plan if their beliefs and expectations are not considered in the decision-making process4; increasingly funding organisations require input from patient partners in grant applications. Similarly, clinicians are unlikely to implement, or even read, research that they find irrelevant to their practice, yet it is rare for funding bodies to require clinician partners in grant applications. However, research teams should strongly value input from clinician partners from research conceptualisation …
P1.12-14 Survival of Patients with Small-Cell Lung Cancer Undergoing Surgical Resection
Authors: S. Kikuchi, J. Okamura, K. Araki, T. Yanagihara, K. Nakaoka, Y. Kitazawa, N. Kobayashi, Y. Goto, Y. Minami, M. Onizuka, H. Ichimura, Y. Sato
Journal: Journal of Thoracic Oncology (2018)